Monopar Therapeutics (MNPR) Change in Accured Expenses: 2016-2024
Historic Change in Accured Expenses for Monopar Therapeutics (MNPR) over the last 9 years, with Dec 2024 value amounting to $506,791.
- Monopar Therapeutics' Change in Accured Expenses rose 83.45% to -$21,418 in Q3 2020 from the same period last year, while for Sep 2020 it was $114,857, marking a year-over-year increase of 325.98%. This contributed to the annual value of $506,791 for FY2024, which is 138.00% up from last year.
- Latest data reveals that Monopar Therapeutics reported Change in Accured Expenses of $506,791 as of FY2024, which was up 138.00% from -$1.3 million recorded in FY2023.
- Monopar Therapeutics' Change in Accured Expenses' 5-year high stood at $1.5 million during FY2022, with a 5-year trough of -$1.3 million in FY2023.
- Over the past 3 years, Monopar Therapeutics' median Change in Accured Expenses value was $506,791 (recorded in 2024), while the average stood at $217,185.
- As far as peak fluctuations go, Monopar Therapeutics' Change in Accured Expenses soared by 265.95% in 2022, and later crashed by 190.21% in 2023.
- Monopar Therapeutics' Change in Accured Expenses (Yearly) stood at $447,598 in 2020, then fell by 9.75% to $403,967 in 2021, then skyrocketed by 265.95% to $1.5 million in 2022, then slumped by 190.21% to -$1.3 million in 2023, then soared by 138.00% to $506,791 in 2024.